Premium
13 C ‐butyrate breath test is a novel non‐invasive screening tool for anti‐inflammatory activity of kampo medicines
Author(s) -
Endo Mari,
Oikawa Tetsuro,
Hoshino Takayuki,
Hatori Tsutomu,
Matsumoto Tsukasa,
Odaguchi Hiroshi,
Hanawa Toshihiko
Publication year - 2017
Publication title -
traditional and kampo medicine
Language(s) - English
Resource type - Journals
ISSN - 2053-4515
DOI - 10.1002/tkm2.1068
Subject(s) - kampo , butyrate , colitis , medicine , excretion , inflammatory bowel disease , inflammation , gastroenterology , sodium butyrate , ulcerative colitis , enema , pharmacology , chemistry , pathology , disease , biochemistry , alternative medicine , fermentation , gene
Aim 13 C ‐butyrate breath test is a non‐invasive method for detecting inflammation in experimental colitis. We investigated whether this test could assess the anti‐inflammatory effect of kampo medicines in dextran sulfate sodium salt ( DSS )‐murine colitis. Methods 13 CO 2 excretion was measured on 13 C ‐butyrate breath test, after rectal instillation of butyrate in a DSS colitis model. Colon length, myeloperoxidase activity, and histological damage were also analyzed to evaluate inflammation. Results 13 CO 2 excretion in the DSS groups was significantly lower than in the normal group. Orengedokuto ( OGT ) and saireito ( SRT ) improve inflammation in DSS murine colitis, and this was reflected in the significantly higher 13 CO 2 excretion in the OGT ‐ and SRT ‐treated DSS murine colitis groups compared with the vehicle (i.e. control) group. Conclusion 13 C ‐butyrate breath test is a new non‐invasive evaluation and screening method for the anti‐inflammatory effect of kampo medicines.